Journals / MN Oftalmoloji / 2015 / Cilt: 22 - Sayı: 4

Hyaluronic Acid Gel Injection in the Treatment of Paralytic Lagophthalmos

Paralitik Lagoftalmi Tedavisinde Hiyalüronik Asit Jel Uygulaması

Pages
237–240
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, novel studies which included comparisons and long-term outcomes are required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the safety and efficacy of hyaluronic acid (HA) gel injection to upper eyelid as a less invasive method in the treatment of paralytic lagophthalmos Material and Method: The cases treated with HA gel injection for paralytic lagophthalmos in the out- patient clinic circumstances have been evaluated retrospectively.
📊
Key Findings & Data:The cases who have suffered lagophthalmos more than 2 months due to facial paralysis which develops after brain tumor operations, the cases who have suffered lagophthalmos due to idiopathic facial paralysis more than 6 months and those who have presented corneal findings were included in the study.
💡
Conclusion & Impact:However, novel studies which included comparisons and long-term outcomes are required.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the safety and efficacy of hyaluronic acid (HA) gel injection to upper eyelid as a less invasive method in the treatment of paralytic lagophthalmos Material and Method: The cases treated with HA gel injection for paralytic lagophthalmos in the out- patient clinic circumstances have been evaluated retrospectively. The cases who have suffered lagophthalmos more than 2 months due to facial paralysis which develops after brain tumor operations, the cases who have suffered lagophthalmos due to idiopathic facial paralysis more than 6 months and those who have presented corneal findings were included in the study. The cases with noticeable dermatological diseases were excluded from the study. HA gel was injected into the deep orbicularis oculi muscle in the pretarsal field. Preoperative and postoperative photographing (eyes and face), palpebral aperture measurements at the open and closed eye status and distance measurements between the center of the pupillary light reflex and upper eyelid margin (MRD1) have been done. These were evaluated with respect to corneal epitheliopathy. The follow-up period examinations were performed at the 1st and the 10th days and within intervals of 3 months after the 1st month. Improved exposure keratopathy, unexposed cornea during sleep and satisfactory cosmetic eyelid appearance were accepted as success criterias for the treatment. Results: Mean patient age was 55.1±1. 5 (25-84) years. Eight eyelids from eight patients have been treated. Of the cases, 3 were female while 5 were male patients. Mean amount of injected HA gel was 1.2 ml (0.9-2.0ml). Mean improvement in lagophthalmos was 4.8 mm (3mm- 6mm; p<0.05). Mean follow-up duration was 11.1±3.9 months (6-15 months). In all cases, the palpebral distance decreased following HA gel injection and exposure keratopathy improved. A second injection was required in none of the cases. The cosmetic appearance was not satisfactory in one case due to excessive amount of HA gel injection. Mild sensitivity and edema were encountered at the injection sites in all cases. Chemosis was noticed in one case. A statistically significant decrease was found in MRD1 after HA gel injection (Z=-2.546;p=0.011<0.05). The decrease in the palpebral distance following HA gel injection measured at open-eye status was found statistically significant (Z=- 2.546;p=0.011<0.05). Also, the decrease in the palpebral distance following HA gel injection measured at closed-eye status was found statistically significant (Z=-2.524;p=0.012<0.05). HA gel injection was successful in 87.5% of the cases. Conclusion: HA gel injection is an effective and safe technique in the treatment of paralytic lagophthalmos. In case of regained good facial nerve functionality, reversible feature of HA gel injection is an advantage depending on its slow resorption. However, novel studies which included comparisons and long-term outcomes are required.

Özet

Amaç: Paralitik lagoftalmi tedavisinde üst kapağa, az invazif bir yöntem olan hiyalüronik asit jel (Teosyal Ultra-Deep) enjeksiyonunun güvenlik ve etkinliğini araştırmak.Gereç ve Yöntem: Paralitik lagoftalmi nedeniyle poliklinik ortamında hiyalüronik asit (HA) jel enjeksiyonu ile tedavi edilen olgular retrospektif olarak değerlendirildi. Beyin tümörü ameliyatlarından sonra gelişen fasiyal paraliziye bağlı lagoftalmide 2 ay, idyopatik fasiyal paraliziye bağlı lagoftalmide 6 ayı geçen ve kornea bulguları olan olgular çalışmaya dahil edildi. Belirgin dermatolojik hastalığı olan olgularçalışma dışı bırakıldı. HA jel pretarsal alana yapıldı. Tedavi öncesi ve sonrası takiplerde; fotoğraf (göz ve yüz) çekimi yapıldı. Hastaların gözaçıkken ve kapalı iken kapak aralığı ölçümü, üst kapak kenarı ile pupil reflesi arasındaki mesafe (MRD1) ölçümü yapıldı, korneal epitelyopatileri değerlendirildi. Takipler 1. ve 10. gün, 1. ay sonrasında 3 ay aralıklarla yapıldı. Açıkta kalma keratitinin düzelmesi, korneanın uyurkenaçıkta kalmaması, kozmetik olarak tatmin edici kapak görüntüsü başarı kriteri olarak kabul edildi.Bulgular: Hastaların ortalama yaşı 55,1±19,5 (25 - 84 yıl) idi. Sekiz hastanın 8 göz kapağına tedavi uygulandı. Enjekte edilen HA jel miktarı ortalama 1,2 mL (0,9-2.0 mL). Lagoftalmideki düzelme ortalama 4,8 mm idi (3mm-6mm; p<0,05). Takip süremiz ortalama 11,1± 3,9 ay (615ay). Tüm olgularda HA jel enjeksiyonu sonrası kapak aralığı mesafesinde azalma, açıkta kalma keratitinde düzelme sağlandı. HA jel enjeksiyon sonrası MRD1'de azalma istatistiksel olarak anlamlı saptandı (Z=-2,546;p=0,011 <0,05). Göz açıkken ölçülen kapak aralığında, HAJenjeksiyonu sonrasındaki azalma istatistiksel olarak anlamlı bulundu (Z=-2,546;p=0,011<0,05). Göz kapalıyken ölçülen kapak aralığında daHA jel enjeksiyonu sonrası azalma, istatistiksel olarak anlamlı bulundu (Z=-2,524;p=0,012<0,05). HA jel enjeksiyonu sonrası olguların %87,5'i başarılıydı.Sonuç: Paralitik lagoftalminin tedavisinde HA jel enjeksiyonu etkili ve güvenilir bir tekniktir. Fasiyal sinir fonksiyonunun geri dönmesi halinde verilen HA jelin yavaş olarak rezorbe olması nedeniyle geriye dönüşümlü olma özelliği bir avantajdır. Ancak karşılaştırmalı ve uzun dönem sonuçları olan çalışmalara ihtiyaç vardır

🔖

Cite This Article

BAŞAR, E., NUHOĞLU, F., ÖZDEMİR, F. E. (2015). Hyaluronic Acid Gel Injection in the Treatment of Paralytic Lagophthalmos. MN Oftalmoloji, Cilt: 22 - Sayı: 4, 237–240. https://ajindex.com/articles/297155

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Tower RN, Dailey RA. Gold Weight Implantation: A Better Way?. Ophtal Plast Reconstr Surg 2004;20:202-6.
  2. Donzis PB, Mondino BJ. Management of noninfectious corneal ulcers. Sur Ophthalmol 1987;32:94-110. Choi HY. Hong SE. Lew JM. Long-term comparison of a newly designed gold implant with the conventional implant in facial nerve paralysis. Plast Reconstr Surg 1999;104:1624. Sheehan JE. Plastic Surgery of the Orbit. New York: Macmil lan, 1927. Jobe R. The use of gold weights in the upper lid. Br J Plast Surg 1993;46:343-4.
  3. Pickford MA, Scamp T, Harrison DH. Morbidity after gold weight insertion in the upper eyelid in facial palsy. Br J Plast Surg 1992; 45:460-4.
  4. Edwards DT, Bartley GB, Hodge DO, et al. Eyelid position meas- urement in Graves' ophthalmopathy: reliability of a photographic technique and comparison with a clinical technique. Ophthal mo - logy 2004;111:1029-34.
  5. Rasband WS. ImageJ. Bethesda, MD: U.S. National Institutes of Health, 1997-2007. Available at: http://rsb.info.nih.gov/ij/. Ru¨fer F, Schro¨der A, Erb C. White-to-white corneal diameter: normal values in healthy humans obtained with the Orbscan II topography system. Cornea 2005;24:259-61. Mancini R. et al. Use of hyaluronic acid gel in the management of paralytic lagophthalmos: the hyaluronic acid gel "gold weight". Ophthal Plast Reconstr Surg 2009;25:23-6. Gold MH. Soft tissue augmentation in dermatology - 2009 update. J Cutan Aesthet Surg 2010;3:2-10.
  6. Monheit GD, Coleman KM. Hyaluronic acid fillers. Dermatologic Therapy 2006;19:141-50.
  7. Klein AW, Beddingfield FC. Other Temporary or Permanent In - jec table Fillers. Klein AW. Tissue Augmentation in Clinical Prac - tice. 2. ed. New York: Taylor & Francis Group 2006;327-36.
  8. Lim JY, Kim HS, Kim YH, et al. PMMA (polymethylmetacrylate) microspheres and stabilized hyaluronic acid as an injection laryn- goplasty material for the treatment of glottal insufficiency: in vivo canine study. Eur Arch Otorhinolaryngol 2008;265:321-6. Malhotra R. Deep orbital sub-Q restylane (nonanimal stabilized hyaluronic acid) for orbital volume enhancement in sighted and anophthalmic orbits. Arch Ophthalmol 2007;125:1623-9.
  9. Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress uri- nary incontinence. Eur Urol 2005;48:488-94.
  10. Goldberg RA, Lee S, Jayasundera T, et al. Treatment of lower eye- lid retraction by expansion of the lower eyelid with hyaluronic acid gel. Ophthal Plast Reconstr Surg 2007;23:343-8.